Showing posts sorted by date for query Satz. Sort by relevance Show all posts
Showing posts sorted by date for query Satz. Sort by relevance Show all posts

Monday, April 17, 2017

A non-directed kidney donor writes eloquently about his experience

Dylan Matthews is eloquent about his decision to give a kidney to a stranger, and explicit about his experience, including post-surgical pain and his recovery. He's well worth reading.

Vox has the story: Why I gave my kidney to a stranger — and why you should consider doing it too

My colleague, the philosopher Debra Satz, points out to me that one of the altruistic donors whose experience motivated Matthews was her student. Philosophy is powerful.

Tuesday, May 19, 2015

Everything for Sale? The Ethics and Economics of Compensation for Body Parts (Video of the panel discussion)

Here's the video of the panel discussion I participated in at Johns Hopkins on May 7, Everything for Sale? The Ethics and Economics of Compensation for Body Parts: the panelists were James Childress, Michele Goodwin, Alvin Roth and Debra Satz

The video, including introductions before and questions after, is an hour and 20 minutes. The introduction by Mario Macis starts around minute 6:40, and includes audience voting on questions of whether they would be in favor of regulated markets for kidneys, for hearts, for blood, for human eggs and sperm, and for breast milk. The panel discussion, moderated by Jeff Kahn, starts at minute 14, with each of the panelists, in alphabetical order, giving an 8 minute opening statement. (Mine begins at 33:20, and ends at 41:41, pretty close to the 8 minute guideline:) .)

Thursday, May 7, 2015

Everything for Sale? The Ethics and Economics of Compensation for Body Parts, at Johns Hopkins, May 7

I'm in Baltimore for the next few days...

The Johns Hopkins Berman Institute of Bioethics
and the Johns Hopkins Carey Business School present
The 2015 Robert H. Levi Leadership Symposium
and Carey Symposium in Markets and Ethics

Everything for Sale?The Ethics and Economics of Compensation for Body Parts
Thursday, May 7, 2015
4:30 p.m. - 6:00 p.m.
Reception to follow

Johns Hopkins School of Nursing
Alumni Auditorium

525 N. Wolfe Street
Baltimore, MD 21205
Welcome:

Ruth Faden
Andreas C. Dracopoulos, Director
and Philip Franklin Wagley, Professor
Johns Hopkins Berman Institute of Bioethics


Bernard T. Ferrari
Professor and Dean
Johns Hopkins Carey Business School


Introduction:

Mario Macis
Assistant Professor of Economics and Management
Johns Hopkins Carey Business School


Panelists include:

Professor James Childress
Professor Michele Goodwin
Professor Alvin Roth
Professor Debra Satz

Moderator:

Jeffrey Kahn
Robert Henry Levi and Ryda Hecht Levi Professor of Bioethics and Public Policy
Johns Hopkins Berman Institute of Bioethics

Wednesday, January 7, 2015

Ethics and Market Design: Stanford, Jan 8 (update, note room change)

If you're on the Stanford campus tomorrow, you're invited to hear a panel discussion, with Anat Admati, Debra Satz and me on repugnance and, more generally, Ethics and Market Design

EVENT OVERVIEW

Markets depend on legal and institutional structures. These structures raise questions of ethics: are they fair? Do they generate harms?  If harms are unavoidable, do these structures fairly manage and distribute the risks of harm?This panel discussion brings together prominent  philosophers and economists to discuss the potentials and limits of designing markets with ethics in mind. Cases in point will be markets for donated organs and financial markets. 
This is an RSVP event. RSVP here.

SPEAKER

Anat Admati, George G.C. Parker Professor of Finance and Economics at the Graduate School of Business, Stanford University, author of The Bankers’ New Clothes: What’s Wrong with Banking and What to Do about It.
Al Roth, Craig and Susan McCaw Professor of Economics at Stanford University & Gund professor of economics and business administration emeritus at Harvard University, winner of the 2012 Nobel Memorial Prize in Economics for his work on market design.
Debra Satz, Marta Sutton Weeks Professor of Ethics in Society, Professor of Philosophy and Political Science, author of Why Some Things Should Not Be for Sale: The Limits of Markets.

4:00PM ON THURSDAY, JANUARY 8, 2015 AT STANFORD LAW SCHOOL, CROWN QUADRANGLE, MANNING FACULTY LOUNGE (ROOM 270)
Sponsored by The McCoy Family Center for Ethics in Society / ethicsinsociety@stanford.edu
***********
Update (with room change) from the organizers:
"Just a quick update on tomorrow's panel discussion: we've been overwhelmed with RSVPs (over 100), so we booked a larger room for the panel discussion (180 in the Law School - we'll put up signposts tomorrow), and we had to close the list for the dinner. "

Monday, December 1, 2014

Experiments as repugnant transactions (if subjects are paid)

Here's a paper that reports a survey of IRB members on whether payments to experimental subjects are coercive. (The focus was on medical trials...)

MONEY, COERCION, AND UNDUE INDUCEMENT: A SURVEY OF ATTITUDES ABOUT PAYMENTS TO RESEARCH PARTICIPANTS
by Emily A. Largent, BSN, Christine Grady, PhD, RN, Franklin G. Miller, PhD, and Alan Wertheimer, PhD, IRB. 2012 Jan-Feb; 34(1): 1–8.

"Nearly all agreed or strongly agreed with the statement that subjects are coerced if they are threatened with harm for not participating (91%). The majority also agreed that participants are coerced if the offer of payment makes them participate when they otherwise would not (65%), or when the offer of payment causes them to feel that they have no reasonable alternative but to participate (82%). Women tended to agree more than men (p = 0.03) that participants are coerced if the payment offer makes them participate when they otherwise would not. No other trends were observed by gender, education, or IRB membership. Most respondents agreed that payment offers are an undue influence if they cause participants to participate when they otherwise would not (81%), if a participant perceives he has no reasonable alternative but to participate (79%), or if the payment offer distorts participants’ evaluation of risks and benefits (98%). "


HT: Debra Satz

Thursday, February 6, 2014

Perfect Strangers: kidney donation movie

I went to see Perfect Strangers last night at Stanford, by Stanford's documentary filmmaker Jan Krawitz.
It was followed by a panel discussion by Krawitz, Stanford philosopher Debra Satz, and two non-directed kidney donors, one of whom was the main character in the film. Both initiated non-directed donor chains.

The other donor was the subject of this 2011 blog post A kidney donor argues that selling kidneys should be legal.

Friday, November 23, 2012

A philosopher looks at repugnant markets

The Dutch philosopher/economist Ingrid Robeyns writes about Roth and Satz on repugnant/noxious markets

She writes that "economists would benefit from explicitly introducing values in their analysis of repugnant markets (and markets in general)," and holds up the work of Debra Satz as a good example of how to go about this.


(Here are my previous posts related to the work of my now-colleague Debra Satz.)

Wednesday, June 6, 2012

Terasaki Medical Innovation award

Itai Ashlagi and I received the NKR Terasaki Medical Innovation award Monday evening at the American Transplant Congress meeting in Boston, for our work on kidney exchange algorithms for patient pools with highly sensitized patients.

"The Terasaki Medical Innovation Award will be presented annually to a medical professional who, through their pioneering work, has had a significant impact in advancing paired exchange transplantation and saving the lives of those facing kidney failure. "

Awards are nice for the recipients, but one can't help but be mpressed by the career of the scientist after whom the award is named, UCLA's Dr. Paul Ichiro Terasaki. Dr. Terasaki pioneered the tests used today to determine immunocompatibility, and built a business to make tools to implement those tests widely available.

Born in California in 1929, he and his family were interned with other Japanese-Americans during WWII. Later in life he donated $50 Million to UCLA, which named their Life Sciences building after him.

In short, he has had a storied scientific and American career.

Also receiving an award Monday evening was the non-directed altruistic donor Alexander Berger, about whom I blogged earlier: A kidney donor argues that selling kidneys should be legal, after he published a NY Times op-ed to that effect. (He's a 2011 Stanford philosophy grad, and he apparently worked with Debra Satz, although they disagree about whether kidney sales should be allowed.) Appropriately enough, he's currently working for an organization called Give Well, which works to identify charities that are "cost-effective, underfunded, and outstanding." He gave well himself, and started a nonsimultaneous extended altruistic donor (NEAD) chain of the kind NKR is famous for.

(I discussed the first NEAD chain here, and have posted about them frequently.)

The food was pretty good too.

Tuesday, May 29, 2012

Michael Sandel on markets and economists

The Boston Review hosts a Forum on Michael Sandel's arguments against markets:

Forum:
How Markets Crowd Out Morals


markets
Shout

Michael J. Sandel


Some economists think markets can benefit all spheres of human activity. But they’re wrong: markets can erode important goods and social norms.


Not only are there some things money can’t buy, but there are also many things it shouldn’t.


Responses



Richard Sennett

When the market is everywhere, we lead a socially impoverished existence.

Matt Welch

Because Sandel disagrees with people’s choices, he wants to take those choices away.

Anita L. Allen

Financial incentives are improperly used to induce African Americans to embrace “good” behaviors.

Debra Satz

Debating the place of the market is less about the value of goods than about inequality.

Herbert Gintis

Tolerance, equality, and democracy have only flourished in market societies.

Lew Daly

Making money, formerly an exclusive realm of cosmic evil, is now “doing God’s work.”

Samuel Bowles

Even market enthusiasts know that society can’t function if people are the amoral, self-interested calculators of blackboard economics.

Elizabeth Anderson

The profit motive is corrupting the justice system.

John Tomasi

Free markets are a kind of fairness.

Michael J. Sandel replies

By keeping markets in their place, we can avoid their corrosive effects.


Sandel lays out his views more fully than in the quote at the top of the page (if not always more clearly) in the lead essay of the forum: How Markets Crowd Out Morals, and in his reply to the commentators, some sympathetic and some less so. Bowles and Welch and Gintis all suggest that the level of the discussion could be raised by considering evidence, of various kinds.

See my earlier posts on Michael Sandel's views on markets.

Update: Nicholas Kristof weighs in in his May 30 NY Times column, citing some of the more lurid examples of things bought and sold.

Thursday, January 6, 2011

Markets, broadly defined

I'm in Helsinki, participating in the second workshop of the Markets & Marketization program, that will bring together philosophers and philosophers of science with economists, sociologists, political scientists and others interested in markets very broadly defined.

Workshop II  Friday-Saturday, 7-8 January, 2011; Tentative program

Friday 7.1.

10.00 - 11.00 Alvin Roth (Harvard): "What does market design teach us about markets?"

11.10 - 11.30 Comment: Patrik Aspers

11.30 - 11.50 Comment: Emrah Aydinonat

11.50 - 12.30 Discussion

14.00 - 15.00 Ronald Noƫ: On biological markets (title TBA)

15.00 - 16.00 Risto Heiskala: "Coordination of human interaction: the BTCIEMP scheme"
(’BTCIEMP’ stands for: biology, traditions, cultural categorization, ideology, economy, military power and political power)

16.30 - 17.30 Jens Beckert: On the sociology of markets (title TBA)

Saturday 8.1.

10.00 - 11.00 Debra Satz (Stanford): The Moral Limits of Markets

11.10 - 11.30 Comment: Adrian Walsh

11.30 - 11.50 Comment: John O’Neill

11.50 - 12.30 Discussion

Wednesday, January 5, 2011

More on the debate over kidney sales: transcript of interview

In my earlier post, Dubner interviews me about kidney sales, I promised to link to a transcript when it became available, and now it has: there's a link at the bottom of the Freakonomics post You Say Repugnant, I Say … Let’s Do It!

Dubner interviewed me for about an hour and a half, so he and his producer Chris Neary had to do lots of editing to produce the half hour or so podcast. I recall a pair of questions, one of which made it into the show and one of which was left on the cutting room floor (or wherever unused electronic files are left).  The question that made it in was about what makes many people view kidney sales as repugnant. The question that didn't make it was, if I were asked to help design a market in which kidneys could be sold, what would be my primary concerns.

Regarding what is behind the repugnance of kidney sales, here's the text of my reply included in the transcript:
"Al Roth: The late Pope John Paul wrote about this and he objects strongly to the sale of kidneys but thinks the donation of kidneys is a very good thing, though if we do it for money is a very bad thing...I think his feeling is that it turns people from ends into means which is a bad thing in itself. So that’s one nature of objection. 
Another kind of objection is that it might be OK if I offered to buy your kidney because you’d be a hard guy to exploit, you’re a successful, financially solvent person, but pretty soon we’d start seeing the desperately poor and maybe they would in some sense be acting against their self interest, they would be being exploited or coerced even, by the temptation of the money in ways that if they could use their better judgement they wouldn’t want to be.  So that’s sort of a coercion argument. 
And then there’s a slippery slope argument that says if we started allowing people to sell their kidneys, it would be primarily poor people who would sell their kidneys, and pretty soon we would start hearing political discussion that said, ‘you know, we don’t really need unemployment benefits, we don’t really need aid to families with dependent children because after all, everyone’s got two kidneys and they can take care of themselves by selling a kidney if they need to’...and that makes us a much less desirable society to live in."


I don't have a transcript to consult about what I said when they asked what I would do if asked to help design a kidney market, but as I recall, my answer went something like this.
The first thing I'd want to think about is what kind of review we would want to use to judge if the market had been a success ten years (or longer) after it had been started. The criteria we'd surely want the market to be evaluated on would include:
 How had the donor/vendors fared?: were they healthy and well treated, and respected, and did they encourage new potential donor/vendors to make the same choices they had?
How had patients with kidney disease fared?: were they receiving healthy kidneys, had the waiting list for transplants largely disappeared, were kidneys being allocated in ways that were widely seen as equitable?


To focus thoughts for future debate, we might want to think about a system in which only the federal government could legally pay for a live kidney, and would have a mandate to set the price (and associated benefits like follow-up medical care) high enough so that there would be a waiting list of donor/vendors, who could e.g. be expected to undergo regular health and suitability tests (suitability being a broad term meant to include physical and mental health, deeply informed consent, etc.)  for a year before being accepted as donor/vendors, and that the kidneys obtained in this way would be allocated anonymously through some regulated procedure that might resemble the current procedures for allocating deceased-donor organs.

In terms of how I've interpreted the ongoing debate between those in favor of sales and those against, I  think that a good deal of the coercion concern can be addressed by an appropriately designed one year waiting period, although I say that without having recently talked to someone who makes that argument with conviction.
I don't see any easy way to bridge the gap between those who think that selling kidneys is a bad thing in and of itself, not to be traded off with possible benefits of other sorts (e.g. to patients and perhaps to donor/vendors), and those who don't see it that way, or who feel that the current dire circumstances of many thousands of those with kidney disease gives legitimate counterweight to this concern.
And the slippery slope concern is the one that personally gives me the most pause. I can see how appropriate legislation would prevent e.g. your bank from asking for a kidney as collateral, but I can't see any way to be sure that making kidneys a potential financial asset wouldn't make us a less sympathetic society (even though a one year waiting period and other qualification tests would limit how much kidney sales could be used as a justification for cutting unemployment insurance in particular).

My work on kidney exchange has largely avoided being enmeshed in this debate, since the "in kind" kidney exchange doesn't seem to arouse repugnance. Thus for example Debra Satz' recent book Why Some Things Should Not Be For Sale: The Moral Limits of Markets, Oxford University Press, 2010, finds little to object to about kidney exchange, but largely disapproves of kidney sales. (I expect to meet Professor Satz for the first time this weekend, at a philosophy of economics conference in Helsinki...)

Wednesday, June 23, 2010

Debra Satz on noxious markets

The Stanford class day speech: Satz to graduates: Some goods should never be for sale by Stanford philosopher Debra Satz, whose interests extend to sales of kidneys

Debra Satz (2008). The Moral Limits of Markets: The Case of Human Kidneys. Proceedings of the Aristotelian Society 108 (1pt3):269-288.

From the news story on her class day address:

"What are the different characteristics of markets? Why do some exchanges prompt "extreme revulsion"? Among the examples Satz raised: child labor, body parts, reproductive services, international arms, addictive drugs.
"What makes particular markets appear undesirable or, in my terminology, noxious?" she asked. The intrinsic nature of certain goods – friendship, a person's good name, various prizes and honor – can immediately diminish their value when they are sold.
There are also extrinsic reasons that make markets noxious, and this was Satz's focus. Is the agent fully aware of the consequences of his or her actions? Do all agents have the same information? Does the market cause extreme harm to individuals? And how extreme does it have to be to make it noxious? Does it cause harm to society?
As Satz said – with a nod to Tolstoy's line about unhappy families – "Each noxious market is noxious in its own way," and there will not be agreement on these issues. For example, the sale of kidneys is among one of the most difficult questions. Sales are illegal in every developed society, she said. Kidneys can be donated altruistically while the donor is alive or after death, but no society makes donation mandatory, even in death. Some would argue that with two kidneys people have more than they need. As of June 10, more than 80,000 Americans were on the waiting list for a kidney, and many of them will die waiting, Satz said. "...

"In closing, Satz threw up two final challenges: "Noxious markets" reflect some of the most fundamental problems of our globe, and they will not go away unless and until the underlying problems are addressed. That will require public debate and a willingness to confront hard issues."

HT: Michael Ostrovsky

And here's Megan McArdle on Satz: What We Should Feel and What We Should Not Sell
She quotes Satz's book Why Some Things Should Not Be for Sale: The Moral Limits of Markets on the following juxtaposition of moral positions:
"[T]here is a dilemma for those who wish to use the mother-fetus bond to condemn pregnancy contracts while endorsing a woman's right to choose an abortion. They must hold it acceptable to abort a fetus but not to sell it."